Back To: Home : Featured Technology : PCR/qPCR

CLICK HERE FOR WHAT'S NEW IN:
 

Seegene, Samsung to co-develop molecular diagnostics
May 2011
SHARING OPTIONS:

ROCKVILLE, Md. & SEOUL, KoreaŚSeegene and Samsung Medical Center have formed a partnership to co-develop molecular diagnostics (MDx) tests for cancer. The partnership combines Seegene's molecular diagnostic technology leadership and Samsung Medical Center's clinical expertise and disease pathology in order to develop new cancer MDx tests. Seegene will be developing new tests for drug resistance and single nucleotide polymorphism as well, which will be based on its multiplex PCR technology (DPO) and real-time PCR technology (READ). The first tests to be developed will be for colon cancer, pancreatic cancer, non-small cell lung cancer and cholangiocarcinoma. These new MDx tests will allow oncologists to profile a patient's tumor to determine if the patient will likely respond to cancer therapies or chemotherapy, and possibly if the cancer will return or metastasize. Dr. Do Hyun Nam, head of the Samsung Medical Center's Institute for Refractory Cancer Research, says "by collaborating with Seegene, it is anticipated to increase the effectiveness of treatment through early diagnosis."

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.